Physician profile
Gregory Moore
NPI 1821023839
$28,245.10
in general payments reported to CMS, 2019-2025
15 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $2,776 · 2021: $17K · 2022: $139 · 2023: $7,151 · 2024: $136 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,307 · Consulting Fee: $1,995 · Food and Beverage: $1,190 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,307.06 |
| Consulting Fee | $1,995.00 |
| Food and Beverage | $1,190.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $18,494.29 | 2020-2021 | |
| Alcon Vision LLC | $6,855.06 | 2023-2025 | Eysuvis, Rocklatan, Simbrinza |
| Novartis Pharmaceuticals Corporation | $1,685.11 | 2019-2021 | |
| Dompe US, INC. | $232.86 | 2022-2024 | Oxervate |
| Carl Zeiss Meditec, INC. | $200.55 | 2019 | |
| The Walman Optical Company | $153.09 | 2025 | |
| Gilead Sciences, INC. | $136.88 | 2023-2024 | |
| Johnson & Johnson Vision Care, INC. | $124.64 | 2023 | Acuvue |
| Coopervision INC. | $99.43 | 2022 | |
| Allergan, INC. | $74.12 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.14 | 2019 | |
| Harrow Eye, LLC | $45.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.48 | 2020 | |
| Daiichi Sankyo INC. | $17.71 | 2022 | |
| Bausch & Lomb Americas INC. | $16.49 | 2024 | Infuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.